{"schema_version":"secwatch.filing_event.v1","accession":"0000313616-24-000223","form_type":"8-K","ticker":"DHR","cik":"0000313616","company_name":"DANAHER CORP /DE/","filed_at":"2024-10-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.682855+00:00","generated_at":"2026-05-30T11:52:52.160750+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Danaher Q3 adj EPS $1.71 beats; revenue $5.8B +3%; guides core rev down low-single digits","bullets":["Net earnings $818M ($1.12 GAAP EPS); adjusted diluted EPS $1.71, above expectations.","Revenue $5.8B, up 3.0% YoY; non-GAAP core revenue grew 0.5%.","Operating cash flow $1.5B, free cash flow $1.2B.","Q4 2024 core revenue expected to decline low-single digits YoY; full year 2024 still down low-single digits.","CEO cites stronger bioprocessing momentum and Cepheid market share gain."],"urls":{"canonical":"https://secwatch.observer/filing/0000313616-24-000223","json":"https://secwatch.observer/filing/0000313616-24-000223.json","markdown":"https://secwatch.observer/filing/0000313616-24-000223.md","text":"https://secwatch.observer/filing/0000313616-24-000223.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/313616/000031361624000223/0000313616-24-000223-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/313616/000031361624000223/dhr-20241022.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T11:52:52.160750+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}